Building Large-Scale Manufacturing Support
If a pharmaceutical customer does not want to perform the BFS fill and finish in their facility, ApiJect has, and is building more, world-class capacity to support their manufacturing needs.
Today, ApiJect has 3 BFS lines at a partnering organization’s facility in South Carolina. Each of these lines have BSL-2 capability and can produce up to an estimated 15 million finished units per month at a 0.3-0.7mL dose fill size. In addition, ApiJect is partnering with other high-quality manufacturing organizations to quickly bring more capacity online to support our customers.
In the coming years, ApiJect will be opening , the new ApiJect Campus and its Gigafactory in North Carolina to greatly expand the manufacturing support we can provide our pharmaceutical customers who do not want to do the fill and finish of their injectable drug products in their facilities.
ApiJect Campus Stats at a Glance
Research Triangle Park, North Carolina, USA
Primary buildings on campus
Number of isolated BFS lines
BFS line features
Aseptic filling, BSL-2 equipped, Temporary cold chain
Cold and freeze chain storage, Large onsite materials stockpile
Projected annual capacity
Up to 2+ billion units
Number of secondary packaging lines
A Compact, Simplified Supply Chain
The supply chain for ApiJect’s medical devices is more compact and flexible than those required for traditional pharmaceutical fill and finish. With a simplified supply chain, continuous operations become far more reliable, even when traditional supply chains are disrupted by a pandemic or other national emergency.
For example, ApiJect’s first device, the Prefilled Injector, requires only two raw materials: pharmaceutical-grade polymer (plastic) and hypodermic needles (made from stainless-steel cannula). Both can typically be sourced domestically and can be stored in large quantities onsite if needed.
To learn more about ApiJect’s devices and technology platform, click here.
Needle Hubs Manufactured Onsite
The ApiJect Campus will have its own Needle Hub Manufacturing Facility onsite. Jointly operated by ApiJect and one of the world’s largest needle and cannula manufacturers, this facility is projected to be able to produce enough Needle Hubs for every BFS Container produced at the Gigafactory, and beyond.
Onsite needle manufacturing further strengthens the ApiJect’s Campus’ reliability to package and deliver finished products on time, enabling it to continue operations, potentially even during emergencies that disrupt global supply chains.
Construction of the ApiJect Campus is now underway. The majority of BFS manufacturing lines are scheduled to be operational by the end of 2023.
To learn more about the ApiJect Campus and how it can serve your company, contact us at firstname.lastname@example.org.